Answers are grounded in this paper and cite their sources.
The selective semi-synthesis of thymol from pulegone, a carcinogenic monoterpenoid, is crucial for regulatory compliance in nutraceutical, pharmaceutical, and flavor industries. A novel 2.5 %Al–1.5 %B–3 %Pd/AC composite was developed as well as validated Al 3+ –B interactions to facilitate cyclohexane ring dehydrogenation, and Pd active sites for selective hydrogenation of C C and C O groups. The catalyst achieved a high thymol yield of 98.5 % under moderate conditions (70 °C, 33 psi H₂, 62 min), and exhibited excellent stability along with maintaining over 95 % activity after five regeneration cycles. Structural analyses confirmed the catalyst's robustness with minimal Pd sintering observed after reuse. Scale-up experiments using Mentha ( CIM-Vishisht ) and DMO oils successfully reduced pulegone content below 0.5 %, meeting stringent safety standards. Additionally, the thymol-enriched products demonstrated strong antimicrobial efficacy against both Gram-negative and Gram-positive strains. This study highlights a promising catalytic approach for selective monoterpenoid valorization and scalable bioactive compound production. • The 2.5 %Al-1.5 %B-3 %Pd/AC catalyst enables selective conversion of pulegone to thymol. • High thymol yield (98.5 %) is achieved under moderate conditions. • Al B species enhance dehydrogenation, while Pd promotes selective hydrogenation. • RSM-BBD optimization provides process scale-up insights.
No takes yet. Share an insight, caveat, or question.
Mohapatra et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: